http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0427904-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a62b0bdfdf0f7834ffb8daa92ec0e61a
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C211-27
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C209-88
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07B57-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C211-27
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C209-88
filingDate 1989-11-16-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_14b1e990fe5c06662b9f3191c9dc6aa8
publicationDate 1991-05-22-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber EP-0427904-A1
titleOfInvention A process for preparing R(+)-terodiline and salts thereof
abstract A novel process for preparing the R(+)-enantiomer of terodiline (N-tert.butyl-1-methyl-3,3-diphenylpropylamine) and pharmaceutically acceptable salts thereof by optical resolution of a racemic mixture of terodiline using tartaric acid, comprises the steps ofn a) removing a major part of the S(-)-terodiline enantiomer from the racemic mixture of terodiline by precipitation with L(+)-tartaric acid in an organic solvent, b) recovering from the mother liquid of step a) a terodiĀ­line product which is enriched in the (+)-enantiomer, c) forming the hydrochloride of said terodiline product in an aqueous solution so as to precipitate R(+)-terodiline hydrochloride from said aqueous solution. n The R(+)-terodiline hydrochloride obtained in step c) is preferablyn d) subjected to one or more re-crystallizations from water. n The R(+)-terodiline hydrochloride obtained from step c) or d) may, if desired,n e) be converted into the free base or into a different pharmaceutically acceptable salt by means of conventionĀ­al procedures.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5492933-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9510269-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6229190-B1
priorityDate 1989-11-16-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID25517
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226521867
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419584606
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129374061
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419538410
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID439655
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419557670
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID222
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID702
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID23479
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419512635
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID23480
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419500914
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID452418832
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID313
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID24755502
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID119400
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419559473
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226458114
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419576422
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419557048
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID25423
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID79698
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID444305
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID451203358
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127836869
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127836867
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419550829
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID962
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID408499458

Total number of triples: 47.